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Abstract
Background: We provide a clinical and analytical evalu-
ation of the reformulated version of the Abbott Architect 
25-hydroxyvitamin D assay. We compared this assay with 
three commercial automated immunoassays and against 
a VDSP-traceable liquid chromatography coupled with 
tandem mass spectrometry (LC-MS/MS) in six different 
populations. We also supplemented 40 healthy volun-
teers with either 600,000 IU of vitamin D2 or 100,000 of 
vitamin D3 to evaluate the performance of the immunoas-
says vs. the LC-MS/MS.
Methods: Precision and limit of quantification were 
assessed, 25(OH)D2 and C3-epimer recovery were calcu-
lated. Two hundred and forty samples obtained in healthy 
Caucasians and Africans, osteoporotic, hemodialyzed and 
intensive care patients and 3rd trimester pregnant women 
were analyzed by all methods. Correlation was studied 
using Passing-Bablok and Bland-Altman analysis. Con-
cordance correlation coefficient (CCC) was calculated to 
evaluate agreement between immunoassays and LC-MS/
MS. We verified if patients were homogeneously classi-
fied with the immunoassays when they took vitamin D2 or 
vitamin D3 after 1, 7 and 28 days.
Results: We observed excellent analytical features 
and showed a very good correlation to the LC-MS/MS 
results in the overall population. Compared to the other 
immunoassays, concordance of the new Abbott assay 
with the LC-MS/MS was at least similar, and often better 
in diseased populations. Althought the cross-reactivity 
with 25(OH)D2 was not of 100%, there was no significant 
difference in the classifications of the patients, either sup-
plemented with D2 or D3 or after 7 or 28 days.
Conclusions: This modified version of the Abbott Archi-
tect assay is clearly improved compared to the previous 
one and presents a better agreement with the LC-MS/MS.
Keywords: assay performance; concordance; immunoas-
say; LC-MS/MS; supplementation; vitamin D; vitamin D2; 
vitamin D3.
Introduction
Due to potential actions of vitamin D on different dis-
eases [1], the number of 25(OH)D determinations has dra-
matically increased over the last 10 years. This increasing 
number of requests have led most the clinical laborato-
ries to move from the DiaSorin RIA, the most widely used 
method in the 1900s and early 2000s, to methods present-
ing a larger throughput, i.e. automated immunoassays or 
liquid chromatographs coupled with two mass spectro-
meters in tandem (LC-MS/MS). External proficiency 
schemes like DEQAS, increasing knowledge on the poten-
tial interferences by 24,25(OH)2D or C3-epimer, need for 
equimolar recognition of 25(OH)D2 and 25(OH)D3 and, 
of course, need for standardization of the assays [2] have 
led manufacturers to improve the performance of their 
assays. In 2012, we published the very first results of the 
validation of the Abbott Architect 25-OH vitamin D assay 
on the i1000SR platform [3]. Our data showed that this kit 
presented excellent performance with coefficients of varia-
tion  < 6% (13.6 ng/mL) and 2.2% (78.1 ng/mL), a functional 
sensitivity of 5 ng/mL and a recovery of 25(OH)D2 of 75.8% 
(95% CI: 61.9–89.7%). We demonstrated that, compared 
to the DiaSorin RIA, the correlation was acceptable if the 
values were  < 50 ng/mL but, above this threshold, a sys-
tematic positive bias was observed, possibly contributed 
by variations of 24,25(OH)2D. In 2015, Abbott Diagnostics 
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launched a reformulated version of their assay. In this 
redesigned version, the pretreatment step of the previous 
version has been eliminated and throughput increased. 
With the new format the calibration stability (30 days) 
and on-board stability (21 days) of the reagents have been 
improved. This new assay is now traceable to the NIST 
SRM 2972 (National Institute of Standards and Technol-
ogy Standard Reference material 2972). In this paper, we 
describe the performances of this reformulated version.
Materials and methods
Analytical validation
Assay precision was determined using serum samples according 
to the CLSI protocol EP05-A2 [4]. Five human serums were run five 
times, in the morning and in the afternoon, for 5 days (n = 50 per sam-
ple). Variability was expressed in standard deviation (SD) and per-
cent coefficient of variation (CV). The analyses were performed with 
the previous assay (ref 3L52, lot 04815I000) and the new one (refer-
ence 5P02, lot 59905UI00) to compare their respective performances. 
Abbott reagents were provided for free and Abbott refunded the labo-
ratory for the costs of the competitors’ reagents.
Clinical validation
Leftover samples: We compared the Abbott Architect assay with our 
VDSP traceable LC-MS/MS and three commercial immunoassays for 
25(OH)D, namely DiaSorin Liaison XL (lot 132394), Beckman Access 
(lot 529187) and Roche Cobas (lot 186865). For this latter method, val-
ues  > 70 ng/mL were censored and could not thus be used for com-
parison purposes.
The first comparison was achieved in 40 healthy subjects span-
ning the measuring range. The second comparison was performed 
with samples obtained from 40 women referred to a specialized oste-
oporosis clinic. We also compared the methods in populations who 
are known to present different vitamin D binding protein (VDBP) 
concentrations or polymorphism: the first one was 3rd trimester 
pregnant women (n = 40) and the second one was African healthy 
subjects from the area of Abidjan, Côte d’Ivoire (n = 40). We also 
compared the methods in a population of 40 stable hemodialyzed 
(HD) patients and in 40 patients from the general intensive care 
unit of our hospital. All the samples used in this study were leftover 
samples kept at –80 °C that underwent one cycle of freeze/thawing, 
which does not alter 25(OH)D values [5]. All the comparisons have 
been performed in parallel on all the instruments by our experi-
enced R&D team, in our ISO 15189 accredited laboratory. The Ethics 
Committee of the CHU de Liege has been informed of the study and 
has accepted its modality.
Supplementation study: Forty healthy volunteers were rand-
omized to receive either 1 ampoule of 100,000 IU of cholecalciferol 
(vitamin D3, D-Cure, SMB, Belgium) or 1 ampoule of 600,000 IU of 
ergocalciferol (vitamin D2, Sterogyl 15, Desma Pharma, France). 
They underwent a blood sampling before supplementation and 
after 24 h, 7 days and 28 days. All the samples were allowed to clot 
for 30 min at room temperature, centrifuged, aliquoted and kept at 
–80 °C until determination in batch with the LCMS/MS, the Abbott 
Architect (versions 3L52 and 3P02) and the Roche Cobas. This part 
of the study has also been performed in accordance with the Ethics 
Committee of the CHU de Liege and the participants gave informed 
consent.
Cross-reactions: The 25(OH)D2 recognition was evaluated with the 
native samples obtained in the supplementation according to the 
method we previously published [6]. The C3-epimer cross-reactivity 
was evaluated in samples containing quantifiable amounts of these 
metabolites as determined with the LC-MS/MS.
Lot-to-lot study: The lot-to-lot consistency was evaluated by run-
ning 172 samples of the validation study for which sufficient volume 
was still available with two other lots, namely lots 60324UI00 and 
60016UI00.
Statistical analysis
The 25(OH)D2 recovery was obtained according to the method we 
previously published [7]. This method was also used to calculate the 
percentage of cross-reactivity with the C3-epimer.
MedCalc software (Oostende, Belgium) was used for the sta-
tistical comparisons and allowed to perform the Passing-Bablok 
regressions and concordance correlation coefficient (CCC) between 
our LC-MS/MS and the three automated assays. The CCC evalu-
ates the degree to which pairs of observations fall on the 45° line 
through the origin [8]. It contains a measurement of precision “r” 
and accuracy Cb and is calculated as CCC = r Cb, where r is the Pear-
son correlation coefficient (which measures how far each observa-
tion deviates from the best-fit line and thus the precision), and Cb 
is a bias correction factor that measures how far the best-fit line 
deviates from the 45° line through the origin, and is thus a measure 
of accuracy. CCC result can be interpreted as follows: poor (  ≤  0.90), 




With the former 3L52 version, the intra-assay CV ranged 
from 10.9% at 5.1 ng/mL to 1.7% at 37.8 ng/mL and the 
inter-assay CV ranged from 13.3 to 2.1% at the same con-
centrations, respectively. With the new 5P02 version, the 
intra-assay CV ranged from 5.2 to 1.7% and the inter-assays 
CV from 5.6 to 2.6% at the same concentrations, respec-
tively. Since the lowest tested value (4.1 ng/mL) presented 
a CV at 5.6% that was far below 20%, it was impossible to 
establish the LOQ.
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Lot to lot variation
Compared to the lot used in this study, the Bland-Alt-
man plot showed mean difference (SD) of 1.2±2.5 and 
2.0±3.0 ng/mL with the A60324UI00 and A60016UI lots, 
respectively and the interval of confidence of the slope of 
the Passing-Bablok regression was comprised between 
0.95 and 1.05, which corresponds to the specifications of 
the manufacturer.
Clinical validation
The Passing-Bablok slopes and intercepts, as well as the 
CCC and quality of the agreement between immunoassays 
and LC-MS/MS, for the global population, but also for all 
the sub-populations are presented in Table 1. To summa-
rize, the agreement was moderate with the new 5P02 kit 
and poor with the former 3L52 version, the Liaison, Cobas 
and Access assays on the overall population (n = 240). This 
agreement was much better in the healthy population: 
substantial for the 5P02 and the Liaison assays, moderate 
for both Cobas and Access and poor for the 3P02. However, 
in the subpopulations, the performances were globally 
poor for all assays, excepted in intensive care patients 
for the 5P02 (substantial) and in osteoporotic patients for 
both Abbott assays (moderate).
The Bland-Altman and Passing-Bablok plots are 
shown in Figures 1 and 2. These plots show that the dis-
persion around the mean difference is much larger with 
the 3L52 assay compared to the other methods. This 
is probably due to the very important over-recovery 
observed in patients presenting the higher 25(OH)-D 
values. On the contrary, the 5P02 version is presenting 
the smallest dispersion. All immunoassays tend to under-
estimate the 25(OH)D concentrations in hemodialyzed 
patients’ samples, the underestimation increasing with 
rising 25(OH)D concentrations. Finally, the Roche Cobas 
assay tended to overestimate the 25(OH)D concentrations 
observed in the healthy Africans group.































































































































































































3rd trimester pregnant women
Figure 1: Bland-Altman plots of Abbott Architect 3L52 and 5P02 assays, DiaSorin Liaison, Beckman Access and Roche Cobas (E) against a 
VDSP-traceable LC-MS/MS method in healthy Caucasian and African subjects, osteoporotic, hemodialyzed and intensive care patients and 
3rd trimester pregnant women.
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3rd trimester pregnant women
Figure 2: Passing-Bablok graphs of Abbott Architect 3L52 and 5P02 assays, DiaSorin Liaison, Beckman Access and Roche Cobas (1E) against 
a VDSP-traceable LC-MS/MS method in healthy Caucasian and African subjects, osteoporotic, hemodialyzed and intensive care patients and 
3rd trimester pregnant women.
The results of the supplementation study are pre-
sented in Figure 3. In the D3 group, five, three, four and two 
subjects presented 25(OH)D values above 30 ng/mL with 
the 3L52, 5P02, Cobas and LCMS/MS assays, respectively. 
After 7 days, they were 12, 11, 11 and 13 and after 28 days, 12, 
12, 11 and 11 of them remained above 30 ng/mL. In the D2 
group, four subjects presented 25(OH)D above 30 ng/mL, 
independently of the method. After 7 days, 19 subjects 
presented 25(OH)D values above 30 ng/mL with the immu-
noassays whereas all of them were above 30 ng/mL with 
the LC-MS/MS. After 28 days, 19 subjects remained above 
30 ng/mL with the LC-MS/MS, 16 with the 3L52 and Cobas 
assays and 14 with the 5P02 one. The χ2-test did not show 
any significant difference in the classifications of the 
patients, either supplemented with D2 or D3 or after 7 or 
28 days. According to the method we previously published 
[6], the D2 recoveries were (95% CI) 68.7% (59.1; 78.3) for 
the 3L52 method, 68.5% (59.2; 77.9) for the 5P02 and 67.6% 
(58.5; 76.8) for the Roche Cobas.
The LC-MS/MS results showed that 37% of the 
samples tested presented C3-epiler concentration higher 
than the limit of detection, set at 2 ng/mL. The mean value 
of C3-epimer in patients presenting quantifiable amounts 
was 6.0±5.0 ng/mL (range: 2.0–33.1 ng/mL). There was a 
significant correlation between C3-epimer and 25(OH-D 
concentrations (Spearman’s ρ = 0.051, p < 0.0001) and 70% 
of them a C3-epimer values ranging between 4.1 and 9.2%. 
Seventy percents of the subjects presenting quantifiable 
C3-epimer concentrations had a C3-epimer/25(OH)D ratio 
comprised between 4.1 and 9.2%. We arbitrarily classified 
the subjects as having low, medium or high C3-epimer 
values if their C3-epimer concentrations were undetect-
able,  < 4 ng/mL,  < 8 ng/mL and above 8 ng/mL. We then 
calculated the mean ratio immunoassay/LC-MS/MS for 
each category. Our results show that this ratio was not 
different across the categories for any of the immunoas-
says. This ratio was neither different when we selected 
healthy subjects presenting no quantifiable C3-epimer 
concentrations.
Discussion
Methods for 25(OH)D determination are continuously 
improving with increasing knowledge on the analytical 
pitfalls linked to this complex determination. We have 
now also a commonly accepted reference method and 
an ongoing worldwide standardization program, the 
Vitamin  D Standardization Program (VDSP) coordinated 
by the CDC, the NIST and the University of Ghent [2]. This 
has led to an increased global concordance of different 
assays in the “normal healthy” population even if some 
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Figure 3: 25(OH)D serum levels observed with Abbott 3L52 and 5P02, Roche Cobas and LCMS/MS assays in 40 healthy individuals 
 supplemented with 600.000 IU of vitamin D2 (Figure 2A) or 100.000 IU of vitamin D3 (Figure 2B) at baseline and after 7 and 28 days.
issues are still remaining, notably in “special” popula-
tions, such as pregnant women, African subjects or hemo-
dialyzed patients [10]. Accordingly, Abbott Diagnostics 
have launched a new version of the Architect 25(OH)D 
assay, calibrated against the NIST SRM 2972. This version 
presents improved analytical features compared with the 
former one, notably a decreased overestimation of the 
25(OH)D in the higher range of concentrations.
The cross-reactivity with 25(OH)D2 is similar to what 
we found previously with the former version. However, 
the results of our supplementation study of healthy volun-
teers with 600,000 of ergocalciferol show that the assay is 
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suitable for monitoring patients receiving vitamin D2 sup-
plements, as in the US or France.
Compared to competing immunoassays, the new 5P02 
assay presents a better agreement with the LC-MS/MS, in 
the global population, but also especially in osteoporo-
tic patients and in patients from the intensive care unit. 
Unfortunately, we did not have the opportunity to compare 
the performances of the 5P02 assay to the Fujirebio Lumi-
pulse we recently validated and which is the only sand-
wich method available for 25(OH)D. Indeed, our results 
had shown that this assay presented a much improved 
clinical concordance compared to the other “classical” 
competitive immunoassays [11].
In conclusion, the new 5P02 version of the Abbott 
Architect 25(OH)D assay is clearly improved compared to 
the previous one.
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